Literature DB >> 20357812

Functional modulation of IGF-binding protein-3 expression in melanoma.

Altaf A Dar1, Shahana Majid, Mehdi Nosrati, David de Semir, Scot Federman, Mohammed Kashani-Sabet.   

Abstract

IGF-binding protein-3 (IGFBP3) is a member of the IGFBP family, which regulates mitogenic and antiapoptotic effects of IGFs. In this report we evaluated the role of IGFBP3 in melanoma. Quantitative real-time PCR (qRT-PCR), western blot, and ELISA analyses indicated a significant downregulation of IGFBP3 expression in melanoma cell lines as compared with a normal melanocyte cell line. Melanoma cell lines treated with the demethylating agent 5-AZA-2'-deoxycytidine reexpressed IGFBP3 at the mRNA and protein levels. Chromatin immunoprecipitation assays revealed enrichment of acetylated histones H3 and H4, and H3 di- and tri-methylated lysine 4 on the unmethylated IGFBP3 promoter. The IGFBP3 promoter region was highly methylated in human melanoma samples as compared with normal nevi. Overexpression of IGFBP3 in melanoma cells in vitro suppressed tumor cell survival, induced apoptosis, reduced colony formation and invasion, and induced expression of the proapoptotic genes p21, PUMA, and BAX. IGFBP3 overexpression also resulted in cleavage of caspase 3 and reduced expression of phosphorylated AKT. Stable overexpression of IGFBP3 suppressed tumor cell growth in vivo. Our study results indicate that silencing of IGFBP3 in melanoma is due to the methylation of its promoter, and that overexpression of IGFBP3 induces apoptosis and suppresses cell survival and growth.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357812      PMCID: PMC3023991          DOI: 10.1038/jid.2010.70

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  51 in total

Review 1.  The insulin-like growth factor-binding protein (IGFBP) superfamily.

Authors:  V Hwa; Y Oh; R G Rosenfeld
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Histone modification enzymes: novel targets for cancer drugs.

Authors:  Rebecca Kristeleit; Lindsay Stimson; Paul Workman; Wynne Aherne
Journal:  Expert Opin Emerg Drugs       Date:  2004-05       Impact factor: 4.191

4.  Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma.

Authors:  Tadashi Hanafusa; Yasuhiro Yumoto; Kazuhiro Nouso; Harushige Nakatsukasa; Toru Onishi; Tatsuya Fujikawa; Mayumi Taniyama; Shinichiro Nakamura; Masayuki Uemura; Yoshitaka Takuma; Eiichiro Yumoto; Toshihiro Higashi; Takao Tsuji
Journal:  Cancer Lett       Date:  2002-02-25       Impact factor: 8.679

5.  Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells.

Authors:  J S Oh; J E Kucab; P R Bushel; K Martin; L Bennett; J Collins; R P DiAugustine; J C Barrett; C A Afshari; S E Dunn
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

6.  Molecular classification of cutaneous malignant melanoma by gene expression profiling.

Authors:  M Bittner; P Meltzer; Y Chen; Y Jiang; E Seftor; M Hendrix; M Radmacher; R Simon; Z Yakhini; A Ben-Dor; N Sampas; E Dougherty; E Wang; F Marincola; C Gooden; J Lueders; A Glatfelter; P Pollock; J Carpten; E Gillanders; D Leja; K Dietrich; C Beaudry; M Berens; D Alberts; V Sondak
Journal:  Nature       Date:  2000-08-03       Impact factor: 49.962

7.  MethPrimer: designing primers for methylation PCRs.

Authors:  Long-Cheng Li; Rajvir Dahiya
Journal:  Bioinformatics       Date:  2002-11       Impact factor: 6.937

8.  Isolation of invasion-associated cDNAs in melanoma.

Authors:  A Gütgemann; M Golob; S Müller; R Buettner; A K Bosserhoff
Journal:  Arch Dermatol Res       Date:  2001-06       Impact factor: 3.017

Review 9.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

Authors:  C M Balch; A C Buzaid; S J Soong; M B Atkins; N Cascinelli; D G Coit; I D Fleming; J E Gershenwald; A Houghton; J M Kirkwood; K M McMasters; M F Mihm; D L Morton; D S Reintgen; M I Ross; A Sober; J A Thompson; J F Thompson
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

10.  Aberrant p27Kip1 promoter methylation in malignant melanoma.

Authors:  J Worm; J Bartkova; A F Kirkin; P Straten; J Zeuthen; J Bartek; P Guldberg
Journal:  Oncogene       Date:  2000-10-19       Impact factor: 9.867

View more
  12 in total

1.  miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein.

Authors:  Altaf A Dar; Shahana Majid; David de Semir; Mehdi Nosrati; Vladimir Bezrookove; Mohammed Kashani-Sabet
Journal:  J Biol Chem       Date:  2011-03-24       Impact factor: 5.157

2.  Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer.

Authors:  Claire M Perks; Jeff Mp Holly
Journal:  J Cell Commun Signal       Date:  2015-04-29       Impact factor: 5.782

Review 3.  Insulin-like growth factor system and sporadic malignant melanoma.

Authors:  Ettore Capoluongo
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

4.  Osteonecrosis of the femoral head: genetic basis.

Authors:  Tracy Wang; Bouziane Azeddine; Wayne Mah; Edward J Harvey; David Rosenblatt; Chantal Séguin
Journal:  Int Orthop       Date:  2018-10-17       Impact factor: 3.075

Review 5.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

6.  Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.

Authors:  Jenny Worthington; Mariana Bertani; Hong-Lin Chan; Bertran Gerrits; John F Timms
Journal:  BMC Cancer       Date:  2010-09-14       Impact factor: 4.430

7.  IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors.

Authors:  Ivonne Regel; Melanie Eichenmüller; Saskia Joppien; Johanna Liebl; Beate Häberle; Josef Müller-Höcker; Angelika Vollmar; Dietrich von Schweinitz; Roland Kappler
Journal:  Mol Cancer       Date:  2012-03-08       Impact factor: 27.401

8.  Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma.

Authors:  Li-Ling Luo; Lei Zhao; Mian Xi; Li-Ru He; Jing-Xian Shen; Qiao-Qiao Li; Shi-Liang Liu; Peng Zhang; Dan Xie; Meng-Zhong Liu
Journal:  Chin J Cancer       Date:  2015-09-14

9.  Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo.

Authors:  Antimo Naspi; Vincenzo Panasiti; Franco Abbate; Vincenzo Roberti; Valeria Devirgiliis; Michela Curzio; Martina Borghi; Francesco Lozupone; Simone Carotti; Sergio Morini; Eugenio Gaudio; Stefano Calvieri; Paola Londei
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

10.  The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression.

Authors:  Altaf A Dar; Shahana Majid; Claudia Rittsteuer; David de Semir; Vladimir Bezrookove; Schuyler Tong; Mehdi Nosrati; Richard Sagebiel; James R Miller; Mohammed Kashani-Sabet
Journal:  J Natl Cancer Inst       Date:  2013-01-30       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.